Henry Ford Health

Henry Ford Health Scholarly Commons
Neurology Articles

Neurology

6-22-2022

Approach to the Management of Sodium Disorders in the Neuro
Critical Care Unit
Murad Baba
Diana Alsbrook
Stacey Williamson
Sandeep Soman
Ahmad R. Ramadan

Follow this and additional works at: https://scholarlycommons.henryford.com/neurology_articles

Curr Treat Options Neurol (2022) 24: 327 –346
DOI 10.1007/s11940-022-00723-6

Critical Care Neurology (H Hinson, Section Editor)

Approach to the Management
of Sodium Disorders in the Neuro
Critical Care Unit
Murad Baba, MD MBA1,*
Diana Alsbrook, MD2
Stacey Williamson, MD1
Sandeep Soman, MD3
Ahmad Riad Ramadan, MD1
Address
*,1

Department of Neurology, Division of Neurocritical Care, Henry Ford Health System,
2799 W Grand Blvd, CFP 466, Detroit, MI 48202, USA
Email:
2
Department of Neurology, University of Tennessee Health Science Center, Memphis,
TN, USA
3
Division of Nephrology and Hypertension, Henry Ford Health System, Detroit, MI,
USA
Published online: 22 June 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

This article is part of the Topical Collection on Critical Care Neurology
Keywords Diabetes insipidus · Hypernatremia · Hypertonic saline · Hyponatremia · Salt wasting · SIADH

Abstract
Purpose of Review To present an overview of the current diagnostic and therapeutic
approaches for patients with hyponatremia and hypernatremia in the neurocritical care
unit (NCCU).
Recent Findings Dysnatremias are associated with poor neurological outcomes and mortality in neurocritically ill patients. Volume status determination, although challenging, is
critical in differentiating between the two most common etiologies of hyponatremia in the
NCCU: SIADH and salt wasting. Central diabetes insipidus (CDI) is common in post transsphenoidal surgery patients and in severe brain injuries where it portends a poor prognosis.
Summary Treatment of dysnatremia should take into account severity of symptoms, rapidity
of onset, and presence and extent of underlying brain injury. Severe acute hyponatremia
is an emergency that should be treated with intravenous hypertonic saline. Controlled

Vol.:(0123456789)

Curr Treat Options Neurol (2022) 24: 327– 346

328

speed of correction is crucial in preventing osmotic demyelination syndrome in the most
vulnerable patients in patients with chronic hyponatremia. SIADH is the most common
cause of hyponatremia in the NCCU and is usually treated with fluid restriction, vaptans,
oral salt, urea, and occasionally saline and loop diuretics. Salt wasting is a common cause
of hypovolemic hyponatremia in severe brain injuries and should be managed with fluid
and salt repletion ± fludrocortisone. Hypernatremia is treated with hypotonic solutions after
correcting volume status as needed with isotonic solution, with the addition of desmopressin or vasopressin in cases of CDI.

Introduction
Disturbances of sodium and water balance are common in intensive care units (ICUs) [1]. The incidence
of dysnatremias is even higher in the neurocritical care
unit (NCCU), encountered in 38% of neurocritically ill
[2] and roughly half of neurosurgical patients [3]. Brain
injury can both induce and result in dysnatremias.
Exquisite sodium and water balance between intracellular and extracellular compartments is required to regulate neuronal and glial physiology, and cell volume.
This balance relies on the intricate interplay between
thirst mechanism, autonomic and cardiovascular systems, hypothalamic–pituitary–adrenal (HPA) axis, and
renin–angiotensin–aldosterone system (RAAS) [4••].

Failure of one or more of these mechanisms to regulate
natremia leads to a plethora of nervous system complications such as encephalopathy, disorders of consciousness, seizures, cerebral edema, osmotic demyelination,
and death [5]. Understanding the pathophysiology
behind the various causes of hyponatremia and hypernatremia is therefore crucial in guiding the approach to
prevent or safely reverse these electrolyte disturbances.
In this review, we delve into the major causes of
hyponatremia and hypernatremia encountered in the
NCCU. We provide an overview of their respective
etiologies, and present approaches to diagnosing and
managing them in the neurocritical care context.

Approach to Hyponatremia in the Neurocritical Care Unit
Epidemiology and Pathophysiology
Commonly defined as a serum sodium (SNa) of less than 135 mEq/L,
hyponatremia affects 3% of hospitalized patients and complicates about
30% of ICU cases [6, 7]. Virtually, any acute brain injury can be associated
with hyponatremia, with conditions as diverse as ischemic and hemorrhagic
strokes, brain tumors, or traumatic brain injury (TBI). The highest incidence
of hyponatremia among neurocritical care illnesses is in subarachnoid hemorrhage (SAH) where it occurs in 40–57% of patients, depending on the series
[8, 9]. Several neurotropic medications commonly used in neurosurgical or
neurocritically ill patients such as anti-seizure and psychiatric medications
can also cause or contribute to hyponatremia. Regardless of the etiology,
hyponatremia has been found to correlate with prolonged ICU stay, mechanical ventilation, and increased mortality among ICU patients [1].
Severity of symptoms caused by hyponatremia depends on the degree and
acuity of development of the electrolyte disturbance. Chronic hyponatremia,
defined as hyponatremia that develops over a period of > 48 h, causes mild
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symptoms and may even be asymptomatic. However, acute hyponatremia
especially when severe (i.e., < 120 mEq/L) can lead to a variety of symptoms
including headaches, nausea, vomiting, drowsiness, and confusion, and can
rapidly progress to seizures, respiratory depression, and fatal cerebral edema.
The reason for this difference in temporal response to hyponatremia lies
in the protective cerebral mechanisms against hypotonicity. Through aquaporin-4 water channels located on glial membranes, water molecules move up
the sodium gradient from extracellular to intracellular compartment, resulting
in astrocytic swelling to spare the neurons [10, 11]. In order to counteract this
increase in water volume, brain cells adapt by extruding osmotically active
solutes into the extracellular compartment. The first solutes to be channeled
out of the cells are the inorganic Na + , K + , and Cl- ions. This initial mechanism occurs in the first 4 h of the adaptive response and accounts for 65%
of the regulatory volume decrease [12, 13]. If hyponatremia persists beyond
48 h, a second mechanism goes into action with the efflux of organic osmoles,
namely glutamate, glycine, taurine, betaine, and myo-inositol. This process
accounts for the remaining 35% of the volume decrease [12, 13]. At 48 h from
hyponatremia onset, the efflux of inorganic solutes still results in a 40% gain
in brain water volume, but after 4 days, the additional extrusion of organic
osmoles reestablishes near normal brain water volume [14, 15].
Although many conditions can lead to hyponatremia, two etiologies are
more frequently encountered in the NCCU: the syndrome of inappropriate
antidiuretic hormone (SIADH) and salt wasting (SW). Both conditions can be
difficult to distinguish on clinical grounds given the similarities in laboratory
and urine studies, but they fundamentally differ in the volume status of the
extracellular fluid (ECF) [8]. In SIADH, the more common condition, there is
a dysregulated release of ADH from the neurohypophysis as a result of brain
injury. This hypersecretion leads to enhanced water retention at the collecting
duct level, leading to a euvolemic or mildly hypervolemic water expansion
state, a hypotonic plasma, and a high urine Na concentration. In SW, on the
other hand, natriuresis occurs in the setting of brain injury, although a renal
origin for this disorder is also posited and proposed as renal salt wasting in
the literature [16•]. For this purpose, we are using the term salt wasting in this
article rather than what it is commonly referred to as “Cerebral Salt Wasting.”
While renal salt wasting in possible in the absence of brain injury, it is very
rare to diagnose salt wasting in the absence of cerebral injuries.
Two main hypotheses for its pathogenesis are entertained: a disturbance
in the sympathetic-driven renal sodium reabsorption, and an enhanced renal
sodium excretion, stimulated by the release of brain (BNP) and atrial (ANP)
natriuretic peptides in response to brain injury. Regardless of the exact mechanism, the outcome in SW is enhanced natriuresis, polyuria, and hypovolemia.
The latter stimulates the appropriate release of ADH, further contributing to
the hyponatremia.
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Hyponatremia in Selected Brain Injuries
Subarachnoid Hemorrhage
Hyponatremia occurs in up to 57% of patients with aneurysmal SAH (aSAH)
[17]. Seventy percent cases are deemed to be SIADH-related, while SW
accounts for 6.5% of cases [17]. SIADH can occur any time and is often
associated with hydrocephalus and anterior circulation aneurysms [17–19],
whereas SW tends to have an early onset and occur in high-grade SAH [20].
SW also tends to precede and parallel the course of vasospasm [21•, 22•, 23],
contrary to previous thoughts that hypernatremia, rather than hyponatremia,
was linked with poor outcomes and mortality in aSAH [24, 25].

Traumatic Brain Injury
Hyponatremia occurs variably in TBI, but can approach 50% of cases in some
studies. It is associated with higher Rotterdam CT score and cranial fractures
[26]. The incidence of SIADH is higher with subdural hematomas and contusions but can also be a part of the triphasic response observed after pituitary
stalk injury; initial phase consists of central DI, second phase consists of
SIADH due to unregulated release of vasopressin, and the third phase is DI
as the damaged hypothalamic neurons can no longer produce ADH.
SW can occur in up to 40% of severe TBI (sTBI) cases and is usually associated with higher morbidity and mortality [27]. Regardless of the etiology,
wide variability in SNa levels may be an independent predictor of mortality
in sTBI [28••].

Stroke
Both acute ischemic stroke (AIS) and spontaneous ICH have been associated
with hyponatremia with an incidence ranging between 11 and 40% [29, 30].
The data about the incidence of SIADH vs. SW in acute stroke is conflicting.
Some reports show that SW accounts for the vast majority of cases, especially
in cases of spontaneous ICH (44 vs. 7%) [30]. Nonetheless, hyponatremia
on admission has been correlated with higher mortality rates at discharge, 3
months, 12 months, and 3 years [29, 31, 32].

Diagnostic Evaluation
The diagnostic approach to hyponatremia and its treatment are important
tools in a neurointensivist’s armamentarium. Once hyponatremia is detected,
a structured approach can be helpful in determining the correct diagnosis and
therefore the appropriate treatment.
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Serum Osmolality
The first step in the diagnostic evaluation of hyponatremia is measurement of
serum osmolality to rule out confounders of true hyponatremia. As noted in
Fig. 1, hyponatremia can exist in hypotonic, isotonic, or hypertonic conditions. Hypotonic and hypertonic plasma are defined by osmolality values
<280 and >295 mOsm/kg, respectively. Isotonic hyponatremia specifically
pseudo hyponatremia is seldom seen since the introduction of ion-selective
electrodes that eliminate the effects of paraproteinemia, hypertriglyceridemia,
and other confounders. Hypertonic hyponatremia occurs in hyperglycemic
states but can also be found with unmeasured osmoles such as mannitol,
an important therapy in the NCCU, especially when it is dosed frequently.
Calculating the osmolar gap, i.e., the difference between measured and calculated osmolality, can lead to the detection of unmeasured osmoles and be
useful in guiding administration of mannitol in cerebral edema management.

Fig. 1.  Diagnostic approach of hyponatremia. *Diuretic use alters the urinary excretion of sodium. In the setting of hypervolemic hyponatremia, urine sodium checked after diuretic use may be higher than expected.
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Volume Status Determination
In the predominant case of hypotonic hyponatremia, volume status assessment
is the next step in the workup. Though a bedside evaluation can be helpful, with
incorporating clinical history, examination of vital signs, jugular veins, mucous
membranes, skin turgor, fluid balance, and blood tests such as hematocrit, BUN,
and bicarbonate, accuracy of this type of evaluation has proven low in various
patient populations [33–35]. In recent years, the use of point-of-care ultrasound
(POCUS) as a non-invasive method to determine volume status at the bedside
has expanded, with measurement of the inferior vena cava being an effective
tool to assess initial fluid status, though less so fluid responsiveness [36]. Formal
echocardiography is more time- and resource-consuming but can give better
insight into a patient’s overall fluid status [35]. Pulmonary artery catheters used
to be the gold standard of hemodynamic monitoring but, in light of their invasiveness and inaccuracies [37], they have largely been supplanted by advanced
hemodynamic monitors that connect to peripheral arterial and/or central venous
catheters which provide a set of dynamic and static hemodynamic measurements
with variable performances [38, 39]. No standalone technique has been shown
effective in determining fluid status or responsiveness, and a comprehensive
evaluation taking into consideration multiple parameters is necessary.

Urine Sodium and Urine Osmolality
As seen in Fig. 1, urine sodium (UNa) and urine osmolality (UOsm) should
then be assessed. In hypervolemic hyponatremia, UNa levels can help differentiate renal failure from other edematous diseases such as cirrhosis, congestive heart failure, and nephrotic syndrome. In hypovolemic hyponatremia,
urine osmolality is high, but UNa can help differentiate renal losses (high)
from extrarenal losses (low). In the euvolemic patient, low UNa and UOsm
point to a diagnosis of polydipsia or low solute intake with relative excess
water ingestion such as beer potomania, while high levels point to SIADH,
hypothyroidism, or adrenal insufficiency. These last two conditions should
always be ruled out as hyponatremia will be resistant to treatment without
adequate hormonal replacement.

SIADH vs. SW
As mentioned earlier, volume status is the only reliable way to differentiate
between the euvolemic SIADH and hypovolemic SW and should therefore
be diligently assessed in the NCCU patient, as the laboratory profiles are
essentially identical (Table 1). In addition to low SNa, both conditions have
high UOsm (above 100 mosmol/kg and usually above 300 mosmol/kg), high
UNa (above 40 mEq/L), and low serum uric acid. One way to differentiate
SIADH and SW by labs, however, is to calculate the fractional excretion of
uric acid (FeUA) after correcting the hyponatremia. The FeUA is high in both
conditions (i.e., >11%). After correction, FeUA will return to normal values
(i.e., 4–11%) in SIADH but remain elevated in SW [40, 41].
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Table 1  Comparison of clinical findings, laboratory values, pathomechanisms, and treatment options between syndrome of inappropriate antidiuretic hormone (SIADH), salt wasting (SW), and central diabetes insipidus (CDI). FeUA,
fractional excretion of uric acid; IV, intravenous; PO, per os

SIADH

SW

CDI

Untreated volume status
Urine output
Serum sodium
Urine sodium
Serum osmolality
Urine osmolality
Uric acid
FeUA before sodium correction
FeUA after sodium correction
Plasma ADH
Pathomechanism

Euvolemic or Hypervolemic
↓
↓
↑
↓
↑
↓
> 11%
4–11%
↑
Free water retention secondary to increased ADH release

Hypovolemic
↑↑
↑
↓
↑
↓↓
↑
4–11%
4–11%
↓
Free water loss secondary to
decreased ADH release

Treatment options

Fluid restriction (if appropriate for clinical setting)
IV hypertonic saline
Oral salt ± loop diuretics
High solute diet
Oral urea
Vaptans

Hypovolemic
↑
↓ or ↓↓
↑↑
↓
↑
↓
> 11%
> 11%
↔
Excessive secretion
of sodium and
water
IV/PO fluid repletion (isotonic or
hypertonic)
Fludrocortisone

IV/PO fluid repletion (hypotonic)
Desmopressin
Low solute diet

Management
The following section on the management of hyponatremia is articulated around
the careful consideration of the following points: (1) severity of symptoms, (2)
acuity of development, (3) SNa level, (4) etiology, (5) volume status, and (6)
presence of brain pathology. A management algorithm is presented in Fig. 2.

Is the Hyponatremia Symptomatic?
Moderately to severely symptomatic hyponatremia, whether acute or chronic,
should be treated as a neurological emergency due to the potential for rapid
development of neurological deterioration and brain herniation. A search for
the cause should never delay treatment, and therefore, regardless of etiology,
symptomatic hyponatremia should be treated with the prompt infusion of
3% NaCl hypertonic saline (HTS). Isotonic saline should be avoided because
it is not efficient at rapidly raising sodium and can exacerbate hyponatremia
in SIADH, in which the real problem is excess free water.
HTS is available in concentrations ranging from 1.5 to 23.4% and may
be given by bolus or continuous infusion. A US expert panel recommends
administering 100 mL 3% NaCl bolus over 10 min up to 3 doses for severe
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Fig. 2.  Approach to the initial management of hyponatremia.

symptoms or start an infusion at a rate of 0.5–2 ml/kg/h for moderate symptoms [42]. The goal is to raise SNa by 4–6 mEq/L, which is usually sufficient
in preventing or reversing neurological deterioration [43, 44]. If symptoms
related to brain herniation persist, repeat boluses may be needed. Note that
symptoms may occur at higher SNa levels in brain-injured patients. During active correction with 3% HTS, SNa should be checked every 4–6 h in
order not to overcorrect and precipitate ODS [42, 45]. Once symptoms have
resolved, HTS therapy can be stopped while SNa continues to be monitored
closely to detect recurrent drops in SNa. A search for etiology should also
be started to direct specific treatment. To prevent development of ODS, we
do not exceed an increase of 10–12 mEq/L in 24 h or 18 mEq/L in any 48-h
period in cases of acute severe hyponatremia [42].
Recent data demonstrated that peripheral administration of HTS in formulations ranging from 3 to 23.4% was as safe and effective as central venous administration, resulting in growing acceptance in NCCU [46••, 47, 48]. Serum K
should be concurrently monitored with SNa because correction of hypokalemia
with oral potassium can speed up the rise in SNa and also because HTS therapy
can worsen hypokalemia. HTS can also cause a hyperchloremic metabolic acidosis that can contribute to renal failure and worsen outcomes. Buffered HTS
(50% chloride, 50% acetate) can lower the chloremic load in such instances.
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Is the Hyponatremia Acute or Chronic?
If symptoms are neither moderate nor severe, the next step is determining
acuity vs. chronicity of the process. If the hyponatremia occurred acutely (< 48
h) but is not severe enough to produce significant symptoms, we recommend
discontinuing potential offenders, starting a diagnostic workup and directing
treatment at the cause [42, 45].
If the hyponatremia is chronic but the patient is known to have an intracranial pathology associated with cerebral edema, a similar approach to the
one detailed above for the symptomatic patient is used. Goal of HTS therapy
depends in part on the degree of edema and mass effect, but as mentioned
earlier, a 4–6 mEq/L rise in SNa is usually enough to prevent neurological
deterioration. Some clinicians, however, aim for normal or even higher SNa
levels in these cases, but an optimal target is unclear.
For the non-brain-injured patient with a mild or moderate chronic
hyponatremia (SNa > 120–134 mEq/L), we recommend discontinuing any
potential offender (medications and hypotonic fluids), limiting water intake,
increasing salt intake, and starting cause-directed treatment [45]. The use of
hypertonic saline in these cases is usually not recommended unless symptoms
develop or worsen.
In chronic severe hyponatremia (SNa < 120 mEq/L), slow HTS administration is recommended while closely monitoring SNa levels every 4 h.
These patients are particularly prone to the development of ODS [49]. This
condition arises from the rapid correction of hyponatremia. The clinical syndrome usually lags behind the rapid correction by 2–6 days and can produce a multitude of irreversible symptoms including bulbar dysfunction,
quadriparesis, confusion, movement disorders, seizures, and coma [50, 51].
Patients at highest risk for ODS are those with SNa < 105 mEq/L for more
than 2 days, hypokalemia, alcoholism, malnutrition, advanced hepatic failure, or liver transplant recipients [49, 52, 53•]. The sodium correction goal for
these patients is more restrictive than in patients at normal risk of ODS: 4–6
mEq/L/day with a limit of 8 mEq/L in 24 h [42]. To prevent overcorrection in
patients with chronic severe hyponatremia, some experts recommend using
parenteral desmopressin but only after achieving a SNa rise of 6–8 mmol/L
during the first 24 h of HTS therapy. In these cases, desmopressin is usually
given at doses of 1–2 mcg either intravenously or subcutaneously, every 6–8
h, until SNa rises above 128 mEq/L [42, 54]. After that, 3% HTS can be continued without desmopressin following the incremental limits given above.
This strategy is however not endorsed by international guidelines and some
experts prefer to reserve the use of desmopressin for when water diuresis
complicates the course of therapy. If overcorrection has occurred, relowering
of SNa to the goal of 4–6 mEq/L in 24 h can be achieved by either giving 2–4
mcg desmopressin parenterally every 8 h or replacing water losses with 5%
dextrose in water (D5W) at a rate of 3 mL/kg/h or based on noted overcorrection and total body water estimate [42, 55]. Total body water calculation
can aid in the management, and may help determine if free water diuresis is
needed to correct the sodium in the absence in brain injuries.
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Special Considerations in the NCCU
The following section focuses on the specific treatment of SIADH and SW,
most commonly encountered in the NCCU. Since fluid management strategies in both conditions are diametrically opposed, making an accurate diagnosis is of utmost importance. Hyponatremia in patients with acute brain
injuries should be managed with the understanding that the majority of these
patients have compromised cerebral autoregulation, cerebral perfusion pressure (CPP), and elevated intracranial pressure (ICP). It is therefore crucial
to optimize volume status in these patients while correcting hyponatremia.
Patients with high-grade aSAH typify this concept. Because of their increased
risk of developing cerebral vasospasm and DCI, high-grade aSAH patients
should not be allowed to become hypovolemic. This is important because
standard therapies for SIADH, such as fluid restriction, vaptans, and loop
diuretics, cause a water deficit and can lead to volume depletion, contributing
to cerebral vasospasm and ischemia. Correction of hyponatremia with HTS
is therefore the preferred strategy in these cases, the goal being maintenance
of a euvolemic state. Similarly, misdiagnosing SW for SIADH can have the
unwanted consequences of worsening both hypovolemia and hyponatremia.

Treatment of SIADH
a. Correction of possible reversible causes should be the first step in management. This means identifying and stopping offending drugs, treating
pain and nausea (powerful stimulators of ADH release) and correcting
adrenal insufficiency and hypothyroidism, if applicable.
b. Fluid restriction is the mainstay treatment for mild to moderate SIADH
but rarely raises SNa level by more than 3–4 mEq/L in 3 days [56•]. To
be effective, the restriction has to create a negative water balance which,
as mentioned above, is not desired in certain neurocritical care patients,
such as those with high-grade aSAH or intracranial hypertension. The
daily fluid intake typically recommended for fluid restriction is based on
calculation of electrolyte-free water clearance (can generally start with
800–1000 mL) which may not be well tolerated by all patients [57].
c. Vasopressin receptor antagonists, or “vaptans,” block V1 and V2 receptors
located in renal connecting tubules and collecting ducts, causing water
diuresis (“aquaresis”). Two vaptans are FDA-approved: conivaptan, an
intravenous, non-selective V1a and V2 receptor antagonist, and tolvaptan, an oral selective V2 receptor antagonist. Tolvaptan was shown to
be effective in treating hyponatremia in two double-blinded RCTs [58].
Conivaptan was studied in the NCCU and found to be effective and safe
in this patient population, with a mean rise of 5.8 mEq/L in 12 h and no
overcorrection [59]. A small open-label study in patients with TBI showed
that conivaptan raised SNa and lowered ICP more effectively than the
usual care arm at 4 h [60]. Vaptans should not be used in volume-deplete
states and we discourage its use in aSAH due to the potential for vasospasm and DCI. Vaptans are also contraindicated in hepatic failure due to
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hepatotoxicity, and liver enzymes should be monitored during therapy.
For this reason, the FDA cautions against their use for longer than 30 days.
The starting oral dose for tolvaptan is 15 mg daily which can be doubled
every 24 h to a maximum dose of 60 mg daily [61]. Conivaptan is given
as an IV bolus of 20 mg over 30 min followed by a continuous infusion
of 20–40 mg over 24 h that can be extended to 96 h. Patients should not
be fluid-restricted during vaptan use in order not to overcorrect [42].
d. Oral salt tablets are used for their osmotic diuresis property. In SIADH,
since sodium handling is intact, the body will excrete the sodium load
and, with it, the volume of water needed to maintain a fixed urine osmolality. A typical regimen is 6–9 g daily in 2 or 3 divided doses (1 g oral salt
contains 17 mEq of Na and 17 mEq of Cl) [62, 63]. Loop diuretics such
as furosemide or torsemide can be added to oral salt tablets to augment
water excretion.
e. Seldom used and only recently introduced in the USA, oral urea is an
inexpensive, well-tolerated, and effective way to treat SIADH [64–67]. Its
mechanism of action is similar to that of oral salt. It is given at doses of
15–60 g daily and is often administered in a powder drink mix to make
it more palatable.

Treatment of SW
a. Fluid repletion is the cornerstone of therapy in SW. Isotonic fluids such
as 0.9% NaCl are frequently chosen for fluid repletion but HTS may be
needed to achieve faster and higher SNa goals, especially in patients with
significant cerebral edema. Different methods for fluid replacement, some
more nursing-intensive than others, have been used in the setting of ongoing polyuria: continuous infusion, intermittent replacement of cumulated
urinary losses (“ml per ml”), or a combination thereof. A detailed assessment of volume status and fluid responsiveness is recommended to guide
fluid replacement in SW.
b. Fludrocortisone, a synthetic mineralocorticoid, enhances Na reabsorption
at the distal convoluted tubule leading to water retention and expansion of the ECF volume. It has been studied in small trials and cohorts
of patients with intracerebral pathology where it was found to improve
hyponatremia and volume status [68–70]. Its effects on mortality, functional outcomes in sICH, and rates of DCI in aSAH are unclear due to
scant data [71]. One of the only RCT on the effect of fludrocortisone in
aSAH showed a statistically non-significant benefit in reducing the rate
of DCI [70]. Typical fludrocortisone dosing in SW starts at 0.05–0.1 mg
twice daily and goes up by 0.1 mg increments to 0.3 mg twice daily, if
needed. Due to its potassium-wasting properties, serum K levels should
be monitored closely during administration.
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Approach to Hypernatremia in the Neuro Critical Care Unit
Epidemiology and Pathophysiology
Hypernatremia, defined as SNa > 145, is a common electrolyte disorder in
critical care, affecting 4–26% of patients [72]. Acute hypernatremia, especially
when severe (> 160 mEq/L), can lead to confusion, lethargy, seizures and
coma. Glial cells and neurons lose water content as a result of the osmotic
gradient. The brain tries to restore its intracellular volume by moving water
from the cerebrospinal fluid into the brain interstitium, followed by early
intracellular uptake of ions and late accumulation of organic osmoles.
In the NCCU, hypernatremia is often a desired therapeutic goal in some settings, particularly in the management of cerebral edema, usually achieved with
osmotherapy. However, hypernatremia can also be unintended, as in diabetes
insipidus, dehydration, or after loop diuretic administration, in which case its
occurrence has been linked to poor outcome in the NCC patient population
[73]. A retrospective review of patients with sTBI at a single US center showed
that mild (defined as 151–155 mEq/L), moderate (156–160 mEq/L), and severe
(> 160 mEq/L) hypernatremia were independent predictors of in-hospital
mortality, with hazard ratios of 3.4, 4.4, and 8.4, respectively (p < 0.001) [74].
The pathogenic link between hypernatremia and poor outcome is thought to
involve neuronal dysfunction and death, myelinolysis, but also cardiac dysfunction, impaired gluconeogenesis, and acute kidney injury via renal vasoconstriction and reduced glomerular filtration [72, 75]. It is important to remember,
however, that hyperchloremia has been extensively recognized as an independent risk factor of poor outcomes in various critically ill patient populations
[76–78]. Although it is difficult to separate the confounding effects of these two
co-occurring electrolyte disorders, a recent study suggests that hyperchloremia,
not hypernatremia, is associated with increased mortality in moderate and sTBI
[79•]. The following discusses the management of hypernatremia, focusing
primarily on central diabetes insipidus (CDI).

Central Diabetes Insipidus
Diabetes insipidus (DI) is a rare disease process with a prevalence of 1 in
25,000 in which patients have decreased responsiveness to (nephrogenic DI)
or release of (CDI) vasopressin. The classic presentation of DI is polydipsia
(greater than 3L/day), polyuria (greater than 50 mL/kg/day), and nocturia
[80•, 81].
Central DI arises from an impaired synthesis of arginine vasopressin (AVP
or ADH) but can also be caused by inadequate secretion alone. It is most
commonly acquired, but can be congenital with mutations in either the AVP
gene or WFS1 gene (Wolfram syndrome) [82]. There can be many causes of
acquired central DI, but the most common causes encountered in the NCCU
are post-operative neurosurgical patients and catastrophic brain injuries, specifically in patients with sTBI and cardiac arrest.
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Transient CDI following transsphenoidal surgery is a known complication,
with incidence reported anywhere from 8 to 30%. The highest risk tumor
pathologies include craniopharyngioma, which has reports of pre-procedural
central DI as well, Rathke cleft cyst, and pituitary adenomas. In one large retrospective single-center study, permanent DI was most common in tumors
originating from Rathke’s pouch [82, 83•].
CDI in patients with injuries to the brain is often associated with poorer
outcomes. CDI after sTBI occurs in 20–26% of patients, may be transient,
and often in a triphasic pattern specifically in deceleration injuries [84, 85].
The initial DI phase is secondary to stunning of hypothalamic AVP neurons
and pituitary stalk transection, and usually lasts 5–7 days [86]. The second
phase, which lasts 2–14 days, is marked by SIADH secondary to large ADH
release from the degenerating posterior pituitary. The third and last phase is
a re-emergence of DI when ADH stores are exhausted and can be permanent
in a minority of patients (6.9% in one cohort) [82, 84, 87•].
In sTBI, studies have shown that development of DI is associated with
higher mortality and worse functional outcomes of survivors [87•]. In cardiac
arrest, studies are not as numerous, but one study looking at out of hospital
cardiac arrest reported outcomes of persistent vegetative state or death in all
post-arrest patients who developed DI [88]. In catastrophic brain injuries,
central DI is a poor prognostic sign and can also be seen just prior to or in
conjunction with the determination of brain death [87•, 88].

Diagnostic Evaluation
Unintended hypernatremia should be worked up, especially when DI is suspected since it can lead to severe hypernatremia, dehydration, and hypovolemic shock, if left untreated. The main distinguishing factor between CDI
and other causes of hypernatremia is the urinary output. Diagnosis is made
based on the clinical features of a high hypotonic urinary output of more
than 50 mL/kg body weight in a 24-h period (polyuria) that leads to the
consumption of more than 3 L/day of water (polydipsia) [80•, 89]. Historically, serologic diagnosis was made using the water deprivation test. Patients
with a urinary osmolality of < 300 mOsm/kg during water deprivation with a
subsequent increase in osmolality of > 50% after administration of exogenous
ADH were diagnosed with CDI [90]. Later studies however proved this test
to have an accuracy of up to only 70% due to various factors. Current studies
are evaluating copeptin, a precursor of ADH, to diagnose CDI as it is more
reliably testable as a surrogate for diagnosis and can be used post operatively
to predict the likelihood of a patient developing CDI [91••].
In the NCCU, hypotonic polyuria is often the heralding sign of CDI
defined as a urinary output of > 200 mL/h for 3 consecutive hours with a urine
specific gravity of < 1.005 or urine osmolality of < 200 mOsm/kg accompanied
by serum sodium levels > 145 mEq/L [92]. The development of a hypovolemic
hypernatremia is most often due to the patient’s impaired cognition, poor
thirst, or limited access to free water to regulate their free water deficit. In
patients already receiving hypertonic saline to induce hypernatremia to serum
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sodium levels > 145 mEq/L due to their primary neurologic injury, the diagnosis relies more on clinical presentation, rate of rise of sodium, and the risk
of developing CDI based on the patient’s neurologic injury. Close monitoring of vital signs and fluid balance should be instituted in all patients with
suspected or known CDI.

Treatment
General Concepts
In any case of hypovolemia, volume resuscitation by administration of isotonic solutions should be performed before efforts to correct hypernatremia
take place. If a loss of free water alone is present, it should be treated by the
administration of free water in the form of a 5% dextrose solution, safe in
terms of hemolysis. If pure sodium gain is the case, natriuresis should be
induced through the application of loop diuretics. At the same time, fluid
loss during loop diuretic therapy must be restored with the administration
of fluid that is hypotonic to the urine [72].
Regardless of the underlying etiology, hypernatremia is treated with hypotonic fluids such as 0.45% NaCl (1/2 NS) or dextrose 5% in water (D5W), the
choice being guided by the desired rate of correction and the hypotonicity
of the replacement fluid. Free water deficit is calculated to gauge the volume
of replacement, using the following equation: 0.5 (females) or 0.6 (males) ×
weight in kg × (measured SNa/ideal SNa – 1). Importantly, a patient who is
hypovolemic or hemodynamically unstable, even if hypernatremic, should
be treated with isotonic fluids until adequately resuscitated.
Carefully considering the speed of correction is of utmost importance to
prevent rebound cerebral edema, particularly in brain-injured patients. This
is determined mostly by the extent and type of brain injury, and the rapidity
of hypernatremia onset. In any case, serum sodium and potassium should
be monitored every 4–6 h during active correction. In acute hypernatremia
(< 48 h in onset), the SNa correction goal is at a rate of 1–2 mEq/L per hour
[72]. In the brain-injured patient, however, normalization may not be the
goal, and a higher SNa and slower correction may be indicated. In chronic
hypernatremia (> 48 h), correction should be slower due to the risk of cerebral edema conferred by the adaptive cerebral mechanisms that take place
when hypernatremia develops over more than 48 h. The recommended rate
of correction in this case is 0.5 mEq/L per hour, with a limit of 12 mEq/L in
24 h [72]. Of note, the rate of correction is more consequential in children
than in adults.

Central Diabetes Insipidus
For central diabetes insipidus, treatment is often guided by the degree of
polyuria. Desmopressin (dDAVP), a synthetic vasopressin analogue, is used
to prevent further urinary water loss [93]. It has a half-life of 3 h and duration of action of 8 h [94]. Intravenous dDAVP 0.5–1 mcg as a starting dose
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is often sufficient to slow urinary output [83•]. This dose may be increased
to 2 mcg if ineffective, or repeated every 6 to 24 h based on the need. The
smallest dose should be used to prevent water intoxication. In the awake
post-transsphenoidal surgery patient, oral replacement with 0.1 to 0.8 mg/day
in 2 or 3 divided doses may be used. Other formulations such as intranasal,
sublingual, or subcutaneous exist but lead to more erratic absorption and
response and are generally not recommended in the neurocritically ill patient.
For patients with underlying TBI or post-cardiac arrest, when hemodynamics are also impaired, intravenous vasopressin infusions may be necessary to
adequately slow urinary water loss [92].
The awake patient whose thirst mechanism is intact should be allowed
access to water and drink to thirst. This helps guide the appropriate desmopressin dosing regimen. In the altered patient who is unable to drink, a
clinical assessment of hemodynamic status to guide fluid replacement and
desmopressin dosing will be needed.

Conclusion
Dysnatremias are increasingly recognized as independent risk factors of poor
outcome in the NCCU. Their diagnostic workup should always include a
careful assessment of volume status and laboratory markers to make a correct diagnosis. This is crucial, for instance, in the appropriate management
of SIADH and SW for which treatment is opposite. Speed of onset, severity
of symptoms, and extent of preexisting brain injury need to be taken into
account when correcting hyponatremia and hypernatremia as rapid overcorrection can lead to osmotic demyelination and cerebral edema, respectively.
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